Annual report pursuant to Section 13 and 15(d)

Condensed Consolidating Financial Statements - Additional Information (Details)

v3.24.1
Condensed Consolidating Financial Statements - Additional Information (Details)
Sep. 08, 2020
USD ($)
Debtinstrument
Jan. 21, 2020
USD ($)
Debtinstrument
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Iterum Therapeutics Bermuda Limited        
Condensed Financial Statements Captions [Line Items]        
Ownership percentage   100.00%    
Subsidiary Guarantors        
Condensed Financial Statements Captions [Line Items]        
Ownership percentage   100.00%    
2025 Exchangeable Notes        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount   $ 9,891,000    
Debt instrument, outstanding principal     $ 11,117,000 $ 12,607,000
Private Placement | 2025 Exchangeable Notes        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount   51,588,000    
Debt instrument price per unit $ 1,000 1,000    
Private Placement | RLNs        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount   $ 103,000    
Number of debt instruments within each notes | Debtinstrument 50 50    
Rights Offering | 2025 Exchangeable Notes        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount $ 220,000      
Rights Offering | RLNs        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount $ 440